Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New role for tamoxifen as fertility drug for breast cancer patients?

08.01.2003


US fertility experts have discovered a potential new role for the wonder drug tamoxifen – helping breast cancer patients to have babies by IVF.



In a study published in Europe’s leading reproductive medicine journal Human Reproduction[1], researchers from New York’s Cornell University report the first IVF pregnancy to result from the use of tamoxifen as an ovarian stimulant.

In a study of 12 breast cancer survivors they found that stimulating the ovaries with a short, carefully timed course of tamoxifen boosted the number of eggs they could retrieve. Every patient had one or more embryos either for freezing for later attempts at pregnancy, or for immediate transfer. One patient who had two fresh embryos transferred has already given birth to twins. Another patient conceived on her second attempt although she miscarried. None of the patients with frozen embryos has yet attempted pregnancy.


Lead researcher Professor Kutluk Oktay said that the experiment arose from a desire to find a safe way of preserving fertility among the 15% of breast cancer patients – around 27,000 annually in the USA – who were still of reproductive age when they were diagnosed.

Chemotherapy causes ovarian failure in many patients – nearly as many as four out of five women in the case of those given cyclophosphamide. Even those who remain fertile or don’t have chemotherapy face the problem of needing a recurrence-free period of perhaps two to five years before trying to conceive, bringing them up against the barrier of infertility due to ageing and diminishing ovarian reserves.

"These women can try natural cycle IVF without ovarian stimulation, but typically, no more than a single embryo can be achieved for immediate use or freezing. So, we need to find a safe way of increasing the number of embryos to give these women a better chance of having a baby," said Professor Oktay, assistant professor of Reproductive Medicine and Obstetrics and Gynaecology at the Center for Reproductive Medicine and Infertility, Weill Medical College of Cornell University.

Tamoxifen was developed in the UK in 1966 as a contraceptive, but found to stimulate ovarian follicle growth and became used in Europe as an ovarian stimulant. (A related compound, Clomiphene, is usually used in the USA). It wasn’t until 1976 that tamoxifen’s suppressive, anti-estrogenic effect on breast cancer was discovered. Since then it has become the world’s most successful anti-cancer drug, saving the lives of thousands of breast cancer patients every year worldwide.

"Sometimes the best ideas are the obvious ones and tamoxifen seemed the obvious choice of drug to test, although, to my knowledge, no one has tried it before in breast cancer patients," said Professor Oktay. "We hypothesised that tamoxifen stimulation would result in higher numbers of embryos compared with natural cycle IVF, while theoretically shielding breast cancer cells against oestrogen."

A retrospective group of five breast cancer patients who had undergone nine cycles of natural cycle IVF was used as a control for the 12 study patients. The 12 patients were given 40-60 mg tamoxifen for around seven days on days 2-3 of their menstrual cycle (a total of 15 treated cycles). The tamoxifen patients produced a greater number of mature eggs than the controls (1.6 versus 0.7) and embryos (1.6 versus 0.6). All tamoxifen patients generated embryos compared with three out of five controls. After a mean follow up of around 15 months none of the study patients has had a recurrence of cancer.

"This is a novel use of tamoxifen to attempt to preserve fertility and treat chemotherapy-related infertility via IVF embryo cryopreservation and embryo transfer after breast cancer," said Professor Oktay. "We exploited tamoxifen’s dual action as an ovarian stimulating drug and an anti-cancer agent."

Because most patients in the tamoxifen group froze their embryos while most in the control group had fresh embryo transfer it has not been possible yet to compare pregnancy rates between the two protocols or to provide long-term data on the effects of tamoxifen on pregnancy. However, long-term experience of the drug in ovulation induction did not suggest an embryo-damaging effect. In any case its use was discontinued prior to ovulation and egg retrieval and IVF embryos were never exposed to it as fertilisation took place in vitro.

Professor Oktay said the study had limitations with its short follow-up and its retrospective, small control group, but a larger study was planned with modifications to the protocol to include low amounts of follicle stimulating hormone (FSH) in addition to tamoxifen.

"I am optimistic," he said. "Many of my patients tell me that just doing something to address the issue of loss of reproductive function makes it easier for them to deal with breast cancer. It connects them to their future and underlines that because they have breast cancer it does not mean they have a terminal illness.

"It would be especially fitting if a drug that has saved so many women’s lives should also turn out to be a means of preserving their fertility," he added.

He urged all breast cancer physicians to be aware of the effect of chemotherapy on women of reproductive age and to refer them to an appropriate assisted reproduction centre as soon as a diagnosis was made so that options for preserving fertility could be discussed.


[1] Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Human Reproduction. Vol. 18. No 1. pp 90-95.

Notes:
1 PDF version of this press release and full embargoed text of the paper with complete results can be found from 09.00hrs GMT Monday 6 January on: http://www3.oup.co.uk/eshre/press-release/jan03.pdf or is available immediately from Margaret Willson.
2 Human Reproduction is a monthly journal of the European Society of Human Reproduction and Embryology (ESHRE). Please acknowledge Human Reproduction as a source.
3 ESHRE’s website is: http://www.eshre.com
4 Abstracts of other papers in ESHRE’s three journals: Human Reproduction, Molecular Human Reproduction & Human Reproduction Update can be accessed post embargo from: http://www3.oup.co.uk/eshre/ Full text of papers available on request from Margaret Willson.

Magaret Willson | EurekAlert!
Further information:
http://www.eshre.com/
http://www3.oup.co.uk/eshre/press-release/jan03.pdf
http://www3.oup.co.uk/eshre/

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>